ATLANTA, GA – – (Newsfile Corp. – December 6, 2021) – – Holzer & Holzer, LLC is investigating whether Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) complied with federal securities laws. On December 6, 2021, the U.S. Food and Drug Administration (“FDA”) released briefing documents ahead of an Advisory Committee meeting regarding CARDINAL, a phase 3 study conducted in support of the New Drug Application for bardoxolone. In the briefing documents, the FDA indicated that the “loss of statistical significance based on a change in a single factor in the analytic model raises concerns regarding the robustness of the study’s findings.” On this news the Company’s stock dropped. If you purchased Reata stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.